Jeffrey Bluestone exits Parker and switches focus back to autoimmune diseases in cell therapy 2.0 launch

Endpoints News

Jeffrey Bluestone steps down as Parker Institute president to develop cell therapies for autoimmune diseases

Jeffrey Bluestone is returning to the scientific field where he forged his reputation as a drug hunter and top investigator.

The prominent scientist has handed in his walking papers as CEO of the high profile Parker Institute for Cancer Immunotherapy, switched to the adjunct faculty at UCSF and is now launching a new company, where he plans to take a hands-on role in the development of new cell therapies for autoimmune and degenerative diseases…